These data demonstrate APOC2‐K70 lactylation serves as a potential biomarker for tumor progression and NSCLC prognosis, and anti‐APOC2K70‐lac Ab has a very promising prospect in NSCLC immunotherapy. This evidence concerns the gene APOC2 and neoplasm.